Publication:
Efficacy of Recombinant Human Interferon alpha-2b on Experimental Endometriosis

dc.authorscopusid24402551000
dc.authorscopusid6701466395
dc.authorscopusid14032375600
dc.authorscopusid7006266820
dc.authorscopusid7003347267
dc.contributor.authorAltintas, D.
dc.contributor.authorKökçü, A.
dc.contributor.authorTosun, M.
dc.contributor.authorÇetinkaya, M.B.
dc.contributor.authorKandemír, B.
dc.date.accessioned2020-06-21T15:13:29Z
dc.date.available2020-06-21T15:13:29Z
dc.date.issued2008
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Altintas] Devrim, Department of Obstetrics and Gynecology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kökçü] Arif, Department of Obstetrics and Gynecology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Tosun] Miǧraci, Department of Obstetrics and Gynecology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Çetinkaya] Mehmet Bilge, Department of Obstetrics and Gynecology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Kandemír] Bedri, Department of Pathology, Ondokuz Mayis Üniversitesi, Samsun, Turkeyen_US
dc.description.abstractObjective: To investigate the efficacy of recombinant human interferon α-2b on endometriosis. Study design: The randomized, placebo-controlled, single-blind, experimental study was performed on 30 Wistar female rats in the Experimental Surgery Laboratory at Ondokuz Mayis University in Turkey. After the peritoneal implantation of endometrial tissue, rats were randomized to two equal intervention groups: (1) the control group and (2) the interferon group. Six weeks later, after implant volume was measured (volume-1) by performing a second laparotomy, interferon α-2b (100,000 IU subcutaneously per rat, three times at 48 h intervals) was administered to the interferon group, and saline solution (0.1 ml SC, once per week), to the control group, for 8 weeks. At the end of the treatment, a third laparotomy was performed to remeasure implant volumes (volume-2), and implants were totally excised for histopathologic examination. Volume-1 and volume-2 within the groups, as well as stromal and glandular tissues between the groups were compared. Results: In the interferon group, volume-2 was statistically significantly reduced compared with volume-1, whereas there was no significant volume change in the control group. In the interferon group, when compared with the control group, both stromal and glandular tissues had statistically significantly lessened. Conclusions: Interferon α-2b was seen to regress significantly both the size and the histological structure of endometriotic implants. © 2007 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejogrb.2007.09.006
dc.identifier.endpage99en_US
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.issue1en_US
dc.identifier.pmid17961906
dc.identifier.scopus2-s2.0-45949110786
dc.identifier.scopusqualityQ2
dc.identifier.startpage95en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2007.09.006
dc.identifier.volume139en_US
dc.identifier.wosWOS:000258042600017
dc.identifier.wosqualityQ2
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofEuropean Journal of Obstetrics & Gynecology and Reproductive Biologyen_US
dc.relation.journalEuropean Journal of Obstetrics Gynecology and Reproductive Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectExperimental Endometriosisen_US
dc.subjectImmunomodulatory Agenten_US
dc.subjectRaten_US
dc.subjectRecombinant Human Interferon α-2ben_US
dc.titleEfficacy of Recombinant Human Interferon alpha-2b on Experimental Endometriosisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files